ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
6 announcements
Kobo Biotech Ltd conducted its 31st Annual General Meeting on July 24, 2026. Shareholders passed the ordinary resolution for adoption of annual accounts and reports.
Kobo Biotech reports that Beaufond Industries failed to implement the NCLT-approved resolution plan by the July 10 deadline. A Monitoring Committee meeting is convened for further action.
Kobo Biotech Ltd submitted its Annual Report for FY 2023-24. The 31st AGM is scheduled for July 24, 2026.
NCLT approved Beaufond Industries' ₹70.11 Crore resolution plan for Kobo Biotech. The plan involves a merger, fresh equity issuance, and settlement of all existing liabilities.
NCLT approved Beaufond Industries' ₹70.11 Crore resolution plan for Kobo Biotech Limited. The plan ensures business continuity through debt settlement and restructuring.
Kobo Biotech Limited confirmed it does not meet the criteria for classification as a 'Large Corporate' (LC) as of March 31, 2026. This disclosure follows SEBI's framework regarding debt securities issuance by large entities.